About: The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on March 1990

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 1990 (ast) наукова стаття, опублікована в березні 1990 (uk) مقالة علمية نشرت في مارس 1990 (ar) scientific article published on March 1990 (en)
publication date	wds:Q37581211-AF4008A0-1131-483D-B49E-9D4EAD444BBB
publication date	1990-03-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37581211-E60BCDB4-89C0-40A3-8F53-A49B30C4B6B5
language of work or name	English
cites work	wds:Q37581211-1203B1F1-098D-4A84-B1C7-3E89450E6AA7 wds:Q37581211-2938E626-1169-43D5-AE50-271765FD1077 wds:Q37581211-345A8268-7184-49A8-AD95-2E3F9A03361C wds:Q37581211-39AB65A0-FB55-4A73-981E-FA38339977B3 wds:Q37581211-58BE0D47-2F3B-4CAA-A7D2-66C07E296A0A
cites work	A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension
author name string	wds:Q37581211-BBBF93AE-F047-4BA7-B7BE-1666EEADEE13
author name string	Lindgren B
rdfs:label	The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (en) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (nl) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (ast)
skos:prefLabel	The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (en) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (nl) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (ast)
name	The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (en) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (nl) The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (ast)
title	wds:Q37581211-FFFC705E-0266-4788-B6FA-1EDC66F53DC1
title	The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden (en)
page(s)	wds:Q37581211-48001A4F-9009-4EAA-89EF-503699D88249
page(s)	748-753
instance of	wds:Q37581211-42B18E22-A70E-4227-B144-0A9A9C06EE77
instance of	scholarly article
main subject	wds:Q37581211-60A5B12C-6BD6-4AF9-B311-ED14912B9F03
main subject	Sweden
PubMed ID	wds:Q37581211-53DD10B1-F2CB-4054-910C-DB1D9DD0467A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1968701
PubMed ID	1968701
published in	wds:Q37581211-E9F1C6A1-E04D-40DD-B313-A5DD17AD6C3A
published in	American Heart Journal
issue	wds:Q37581211-8767052C-1BC1-4039-B96C-04E92129F713
volume	wds:Q37581211-EC091357-365E-44BF-B75B-001E59E2C2F3
issue	3 Pt 2
volume	119
DOI	wds:Q37581211-BD74E247-CF89-4F41-9CC4-C55C0F489594
DOI	http://dx.doi.org/10.1016/S0002-8703(05)80056-0
DOI	10.1016/S0002-8703(05)80056-0
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37581211
is cites work of	Angiotensin-converting enzyme inhibitors Cost-effectiveness analysis of the use of digoxin immune Fab(ovine) for treatment of digoxin toxicity Low-cost therapeutic agents. Uses and abuses
is cites work of	wds:Q34236623-051BFC6C-35FA-48CE-86CF-43AAF45FC3B1 wds:Q74265309-12C6F516-A6EB-4FA4-BDE4-E7EFD21D1693 wds:Q43914955-7A959F1F-5852-4A00-8577-D60F6AA49BD3

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software